Skip to main content
. 2022 Jan 17;11:670897. doi: 10.3389/fonc.2021.670897

Table 2.

Baseline characteristics of postmenopausal breast cancer patients.

VARIABLE Control (n = 182) TAM (n = 198) LET (n = 151) ANA (n = 118) EXE (n = 82) F/X2 P
Age, mean (SD) 57.12 (6.53) 53.35 (6.44) 58.99 (6.48) 59.18 (6.81) 61.07 (8.51) 95.09 <0.01
Smoking, n (%) 8.47 0.076
 Yes 0 (0.00%) 5 (2.53%) 1 (0.66%) 1 (0.85%) 1 (1.22%)
 No 182 (100.00%) 193 (97.47%) 150 (99.34%) 117 (99.15%) 81 (98.78%)
hypertension, n (%) 9.98 0.041
 Yes 7 (3.85%) 9 (4.55%) 13 (8.61%) 14 (11.86%) 7 (8.54%)
 No 175 (96.15%) 189 (95.45%) 138 (91.39%) 104 (88.14%) 75 (91.46%)
BMI, mean (SD) 23.15 (3.13) 23.66 (3.00) 23.85 (3.15) 24.68 (3.58) 23.52 (2.90) 4.39 <0.01
Surgery, n (%) 15.10 0.06
 Mastectomy 15 (8.24%) 3 (1.52%) 8 (5.30%) 11 (9.32%) 8 (9.76%)
 Breast conserving operation 164 (90.11%) 193 (97.47%) 142 (94.04%) 107 (90.68%) 73 (89.02%)
 Breast reconstruction 3 (1.65%) 2 (1.01%) 1 (0.66%) 0 (0.00%) 1 (1.22%)
chemotherapy, n (%) 113.81 <0.01
 anthracycline-plus-taxane based regimens 113 (62.09%) 144 (72.73%) 90 (59.60%) 71 (60.17%) 42 (51.22%)
 Anthracycline based regimens 2 (0.01%) 9 (0.05%) 1 (0.01%) 0 (0.00%) 20 (24.39%)
 Taxane based regimens 67 (36.81%) 45 (22.73%) 60 (39.74%) 47 (39.83%) 20 (24.39%)
TNM stage, n (%) 14.03 0.08
 Stage I 54 (29.67%) 54 (27.27%) 39 (25.83%) 37 (31.36%) 31 (37.80%)
 Stage II 127 (69.78%) 136 (68.69%) 111 (73.51%) 80 (67.80%) 50 (60.98%)
 Stage III 1 (0.55%) 8 (4.04%) 1 (0.66%) 1 (0.85%) 1 (1.22%)
Baseline TC level, mean (SD) 5.22 (0.97) 5.07 (0.95) 5.24 (1.03) 5.28 (1.07) 5.19 (0.94) 1.14 0.34
Baseline TG level, mean (SD) 1.82 (1.14) 1.77 (1.05) 1.81 (0.79) 1.87 (0.87) 1.66 (0.83) 0.62 0.65
Baseline LDL level, mean (SD) 3.16 (0.85) 3.00 (0.76) 3.27 (0.79) 3.35 (0.79) 3.12 (0.83) 4.42 <0.01
Baseline HDL level, mean (SD) 1.45 (0.40) 1.39 (0.42) 1.39 (0.32) 1.42 (0.36) 1.51 (0.46) 1.96 0.10